Myovant Stock Continues Upward After Accepting $2.9B Deal
Myovant Sciences Ltd.'s stock rose about 9% Monday following an announcement that it had accepted a boosted go-private takeover bid from its Japan-based majority stakeholder Sumitovant Biopharma Ltd. at an enterprise...To view the full article, register now.
Already a subscriber? Click here to view full article